Author

Nidhi Shukla

Observed name: N Shukla

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

ORCID: 0000-0002-7581-3861

Observed ORCID: 0000-0002-7581-3861

OpenAlex ID: A5123499765

Assoziation endoskopischer Ergebnisse mit langfristigen klinischen Verbesserungen bei Patienten mit mittelschwer bis schwer aktivem Morbus Crohn, die mit Upadacitinib behandelt wurden: Ergebnisse aus der U-ENDURE Langzeit-Erweiterungsstudie

2026 · E V Loftus, E Louis, et al. · Zeitschrift für Gastroenterologie

Trends in Corticosteroid Use and Excess in Patients With Inflammatory Bowel Disease in the United States, Sweden, and Denmark

2026 · Tim Raine, Gil Y. Melmed, et al. · JCC Plus

Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study

2026 · Edward V. Loftus, Namita Joshi, et al. · The American Journal of Gastroenterology

P0774 Long-term sustained improvement of health-related quality of life, work productivity and fatigue in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study

2026 · J Panés, E Louis, et al. · Journal of Crohn s and Colitis

P0749 Association of endoscopic outcomes with long-term clinical improvements in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study

2026 · E Loftus, E Louis, et al. · Journal of Crohn s and Colitis

Works count: 5

Citation count:

H-index:

I10-index: